Related Experiment Videos
Staphylococcus aureus with reduced susceptibility to vancomycin--Illinois, 1999
Abstract:
Staphylococcus aureus is one of the most common causes of hospital- and community-acquired infections. Nosocomial methicillin-resistant S. aureus (MRSA) infections have become common, and cases of community-acquired MRSA infections also have occurred. Since 1996, vancomycin-intermediate S. aureus (VISA; vancomycin minimum inhibitory concentration [MIC = 8-16 microg/mL) has been identified in Europe, Asia, and the United States. The emergence of reduced vancomycin susceptibility in S. aureus increases the possibility that some strains will become fully resistant and that available antimicrobial agents will become ineffective for treating infections caused by such strains. This report describes the fourth case of confirmed VISA from a patient in the United States.
Insights
Vancomycin-intermediate Staphylococcus aureus (VISA) infections are emerging globally. This report details the fourth confirmed U.S. case of VISA, highlighting the growing threat of antibiotic resistance.
Area of Science:
- Infectious Diseases
- Microbiology
- Antimicrobial Resistance
Background:
- Staphylococcus aureus is a leading cause of hospital and community infections.
- Methicillin-resistant S. aureus (MRSA) is a significant public health concern.
- Vancomycin is a critical antibiotic for treating severe S. aureus infections.
Observation:
- Vancomycin-intermediate S. aureus (VISA) strains, with reduced susceptibility to vancomycin (MIC = 8-16 microg/mL), have been identified since 1996.
- VISA has been reported in Europe, Asia, and the United States.
- This report documents the fourth confirmed case of VISA in a U.S. patient.
Findings:
- The emergence of VISA strains signifies a step towards complete vancomycin resistance in S. aureus.
- Reduced vancomycin susceptibility complicates treatment options for S. aureus infections.
Implications:
- The increasing prevalence of VISA strains raises concerns about the future effectiveness of vancomycin.
- This underscores the urgent need for novel antimicrobial strategies and vigilant surveillance of antibiotic resistance.
- Continued monitoring and research are essential to combat the threat of untreatable S. aureus infections.